90271-04-8

Basic information

• Product Name: Hydrazinecarboxylic acid, 2-acetyl-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Hydrazinecarboxylic acid, 2-acetyl-, 1,1-dimethylethyl ester (9CI)
• CAS NO: 90271-04-8
• Molecular Formula: C₇H₁₄N₂O₃
• Molecular Weight: 174.19766
• Product Categories: N-BOC
• Mol File: 90271-04-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Hydrazinecarboxylic acid, 2-acetyl-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Hydrazinecarboxylic acid, 2-acetyl-, 1,1-dimethylethyl ester (9CI)(90271-04-8)
• EPA Substance Registry System: Hydrazinecarboxylic acid, 2-acetyl-, 1,1-dimethylethyl ester (9CI)(90271-04-8)

Safety Data

• Hazardous Substances Data: 90271-04-8(Hazardous Substances Data)

Upstream product

• 870-46-2 t-butoxycarbonylhydrazine 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 64-19-7 acetic acid 

Downstream Products

• 1068-57-1 acetic acid hydrazide 

Relevant articles and documents

Design and discovery of 6-[(3 s,4 s)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1-(tetrahydro-2 h -pyran-4-yl)-1,5-dihydro-4 h -pyrazolo[3,4- d ]pyrimidin-4-one (PF-04447943), a selective brain penetrant pde9a inhibitor for the treatment of cognitive disorders

6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl] -1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943) is a novel PDE9A inhibitor identified using parallel synthetic chemistry and structure-based drug design (SBDD) and has advanced into clinical trials. Selectivity for PDE9A over other PDE family members was achieved by targeting key residue differences between the PDE9A and PDE1C catalytic site. The physicochemical properties of the series were optimized to provide excellent in vitro and in vivo pharmacokinetics properties in multiple species including humans. It has been reported to elevate central cGMP levels in the brain and CSF of rodents. In addition, it exhibits procognitive activity in several rodent models and synaptic stabilization in an amyloid precursor protein (APP) transgenic mouse model. Recent disclosures from clinical trials confirm that it is well tolerated in humans and elevates cGMP in cerebral spinal fluid of healthy volunteers, confirming that it is a quality pharmacological tool for testing clinical hypotheses in disease states associated with impairment of cGMP signaling or cognition.

COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES

Compounds of the general formula I and their use for treating medical disorders resulting from a deficiency in growth hormone.

Growth hormone secretagogues derived from NN703 with hydrazides as C- terminal

A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.